Connexin-43 is a promising target for pulmonary hypertension due to hypoxaemic lung disease
Claire Bouvard, Nafiisha Genet, Carole Phan, Baptiste Rode, Raphaël Thuillet, Ly Tu, Paul Robillard, Marilyne Campagnac, Raffaella Soleti, Eric Dumas De La Roque, Frédéric Delcambre, Laurent Cronier, Thibaud Parpaite, Elise Maurat, Patrick Berger, Jean-Pierre Savineau, Roger Marthan, Christophe Guignabert, Véronique Freund-Michel, Christelle Guibert
Source: Eur Respir J, 55 (3) 1900169; 10.1183/13993003.00169-2019
Disease area: Pulmonary vascular diseases
Rating:
You must login to grade this presentation.
Share or cite this content
Citations should be made in the following way:
Claire Bouvard, Nafiisha Genet, Carole Phan, Baptiste Rode, Raphaël Thuillet, Ly Tu, Paul Robillard, Marilyne Campagnac, Raffaella Soleti, Eric Dumas De La Roque, Frédéric Delcambre, Laurent Cronier, Thibaud Parpaite, Elise Maurat, Patrick Berger, Jean-Pierre Savineau, Roger Marthan, Christophe Guignabert, Véronique Freund-Michel, Christelle Guibert. Connexin-43 is a promising target for pulmonary hypertension due to hypoxaemic lung disease. Eur Respir J, 55 (3) 1900169; 10.1183/13993003.00169-2019
You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
Related content which might interest you:
Related content which might interest you: